Michael J. Curran, EVP & Chief Administrative OfficerM. Joy Drass, MD, EVP & Chief Operating OfficerStephen R.T. Evans, MD, EVP & CMOOliver M. Johnson II, EVP & General CounselKevin P. Kowalski, Senior Vice President, Marketing and StrategyJennie P. McConagha, Senior Vice President and Chief of StaffSusan K. Nelson, EVP and CFOEric R. Wagner, EVP Insurance and Diversified OperationsMedStar Health is a not-for-profit healthcare organization. It operates more than 120 entities, including ten hospitals in the Baltimore–Washington metropolitan area of the United States. In 2011 it was ranked as the employer with the largest number of local employees in the region.MedStar pays approximately $111 million in payroll tax to the District of Columbia, Maryland and Virginia each year. Additionally, as of 2012, MedStar Health provided almost $312 million in charity care and community benefit on an annual basis.T.
Objective: To evaluate the association between mechanical thrombectomy (MT)& horbar;combined with standard wound care and adjunctive endovenous interventions, as indicated & horbar;and venous wound healing in patients with post-thrombotic venous obstruction. Methods: This multicenter, retrospective analysis included adults with venous wounds secondary to lower-extremity deep vein thrombosis. MT was performed with one or more of the following devices (Stryker): ClotTriever System, ClotTriever BOLD catheter, or VenaCore catheter in native vessels, or RevCore catheter (Stryker) within occluded stents. Adjunctive venoplasty and stenting were performed as indicated. Standard wound care continued until wound healing or latest follow-up. Technical success was defined as crossing the lesion and deploying the study device; clinical success as any decrease from baseline in wound area. Results: Twenty-two patients with 37 wounds on 29 limbs were treated between August 2021 and September 2024. Mean age was 59.0 +/- 12.8 years, and 72.7% were male. More than half had failed conservative wound care before referral; three had been referred for amputation. Median wound duration was 13.0 [interquartile range (IQR), 6.3-45.0] months. Technical success was achieved in 100% of cases; all procedures were single session, with 91.7% performed outpatient. Stenting was performed in 15 of 29 limbs (51.7%) and venoplasty in 23 of 29 (79.3%). Among the 14 limbs without new stenting at the index procedure, two underwent MT alone and 11 received adjunctive venoplasty only. No adjunctive thrombolytics were used. Hospital stay (median, 2; IQR, 2-2.75 days) was required following six procedures. At latest follow-up (median, 2.8; IQR, 2.0-3.5 months), all wounds were healed or healing, meeting the clinical success definition. Among the 25 wounds with available area data, mean wound area decreased from 22.0 +/- 30.9 cm2 at baseline to 5.1 +/- 20.8 cm2, with a mean per-wound area reduction of 91.4%; 76% (19/25) fully healed, and the remaining wounds showed a mean per-wound area reduction of 65.6%. Conclusions: In this multicenter retrospective analysis, all patients with post-thrombotic venous wounds were healed or healing at latest follow-up after MT, with a 91% mean per-wound area reduction. These findings suggest that MT & horbar;combined with standard wound care and adjunctive endovenous interventions as indicated & horbar;may play an important role in treating recalcitrant post-thrombotic venous wounds. (J Vasc Surg Venous Lymphat Disord 2027;15:102625.)
BACKGROUND:Whether anticoagulation alone is an adequate treatment for acute, intermediate-risk pulmonary embolism is uncertain. METHODS:We conducted a multinational, adaptive-design trial with blinded outcome adjudication. Patients with intermediate-risk pulmonary embolism (with a ratio of right ventricular end-diastolic diameter to left ventricular end-diastolic diameter of ≥1.0 and an elevated troponin level) were eligible if they had at least two indicators of cardiorespiratory distress (systolic blood pressure of ≤110 mm Hg, a heart rate of ≥100 beats per minute, or a respiratory rate of >20 breaths per minute). Patients were randomly assigned to undergo ultrasound-facilitated, catheter-directed fibrinolysis with alteplase plus anticoagulation (the intervention group) or anticoagulation alone (the control group) according to prespecified treatment protocols. The primary outcome was a composite of pulmonary embolism-related death, cardiorespiratory decompensation or collapse, or symptomatic recurrence of pulmonary embolism within 7 days. RESULTS:The intention-to-treat population comprised 544 patients: 273 in the intervention group and 271 in the control group. The mean (±SD) age was 58.2±13.5 years, and 42.6% of the patients were women. A primary-outcome event occurred in 11 patients (4.0%; 95% confidence interval [CI], 2.3 to 7.1) in the intervention group and 28 (10.3%; 95% CI, 7.2 to 14.5) in the control group (relative risk, 0.39; 95% CI, 0.20 to 0.77; P = 0.005). The effect was driven primarily by a lower risk of cardiorespiratory decompensation or collapse in the intervention group. Major bleeding occurred within 7 days after randomization in 11 patients (4.1%) in the intervention group and 6 (2.2%) in the control group (P = 0.32); major bleeding occurred within 30 days in 11 patients (4.1%) and 8 patients (3.0%), respectively (P = 0.64). No substantial between-group differences in the incidence of other serious adverse events were observed up to 30 days after randomization; no intracranial hemorrhage occurred. CONCLUSIONS:In patients with acute, intermediate-risk pulmonary embolism, ultrasound-facilitated, catheter-directed fibrinolysis plus anticoagulation led to a lower risk of the composite of pulmonary embolism-related death, cardiopulmonary decompensation or collapse, or symptomatic recurrence of pulmonary embolism within 7 days than anticoagulation alone. (Funded by Boston Scientific; HI-PEITHO ClinicalTrials.gov number, NCT04790370.).
Liver infections comprise a large category of hepatic diseases which vary in etiology and geographic distribution. They remain a significant cause of morbidity and mortality globally and require prompt diagnosis and management. Because clinical and laboratory findings may not be definitive, imaging often plays an important role in the diagnosis, characterization, and follow-up of hepatic infections. Advanced imaging techniques increase accuracy of diagnosis of specific infectious pathogens and in some cases provide the means of differentiation of various infections from other hepatic pathologies and conditions, most notably, neoplasms. Radiologists must be familiar with the key imaging findings and differential features in the multimodality approach to these conditions. This review provides a comprehensive overview of common and uncommon hepatic infections, highlighting key imaging features, characteristic signs, differential diagnoses, complications, and treatment considerations. Advanced techniques utilizing major cross-sectional modalities, including but not limited to contrast-enhanced ultrasound, dual energy computed tomography, and diffusion-weighted and contrast-enhanced magnetic resonance imaging will be discussed. A summary table that combines clinical, laboratory, demographic data and imaging findings will also be provided to guide diagnostic evaluation. This article aims to equip radiologists with essential tools for accurate diagnosis and timely clinical guidance.
Inconsistencies in healthcare access, varying infrastructure, resource constraints and diverse local practices as well as practical and political issues restrict the global applicability of currently available guidelines. There is a need for universal recommendations that address the unique challenges faced by patients and healthcare providers worldwide. Our iCARDIO Alliance Global Implementation Guidelines emphasize the incorporation of novel therapies, while integrating standard of care with the most up-to-date evidence to enable clinicians to optimize patient care. This document is about heart failure (HF), including acute and chronic heart failure, heart failure with reduced ejection fraction and heart failure with preserved ejection fraction as well as cardiomyopathies. Context-specific recommendations tailored to individual patient needs are highlighted providing a thorough evaluation of the risks, benefits, and overall value of each therapy, aiming to establish a standard of care that improves patient outcomes and reduces the burden of hospitalization in this susceptible population. These guidelines provide evidence-based recommendations that represent a group consensus considering the many other published guidelines that have reviewed many of the issues discussed here, but they also make new recommendations where new evidence has recently emerged. Most importantly these guidelines also provide recommendations on a number of issues where resource limitations may put constraints on the care provided to HF patients. Such "economic adjustment" recommendations aim to provide guidance for situations when "Resources are somewhat limited" or when "Resources are severely limited". Hence, this document presents not only a comprehensive but also concise update to HF management guidelines thereby aiming to provide a unified strategy for the pharmacological, non-pharmacological, invasive and interventional management of this significant global health challenge that is applicable to the needs of healthcare around the globe.
Depression is common and often difficult to monitor for clinical worsening in real-world settings where structured symptom scales are inconsistently captured. Electronic health records allow large cohort analyses. Diagnostic-code based definitions offer a practical way to identify patients at risk for progression. We used a multi-institutional dataset (MedStar Health) to study adults with mild depression and evaluated whether machine learning models could predict progression to moderate or severe depression within two years. The cohort included 803 individuals with two years of continuous follow-up. A broad set of demographics, clinical, laboratory, socioeconomic, and healthcare utilization features was available. Models included logistic regression, random forest, gradient boosted trees, and a deep neural network (DNN). Gradient boosted trees showed balanced performance, defined as a trade-off between sensitivity and specificity with a modest improvement over baseline prevalence, while logistic regression demonstrated the strongest overall discrimination and generalization. The DNN showed lower accuracy than null classifier. These findings demonstrate that real-world EHR data can support risk prediction of depression worsening with stable and clinically relevant performance. These models may support earlier identification of patients who warrant closer monitoring or targeted follow-up.